VU0652925
| Code | Size | Price |
|---|
| TAR-T29140-5mg | 5mg | £1,091.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T29140-50mg | 50mg | £2,143.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T29140-100mg | 100mg | £2,801.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
VU0652925 is a PAR4 antagonist. VU0652925 has a P-sel IC50 of 39.2 pM (-pIC50?SEM: 10.41?0.04) and a PAC1 IC50 of 43.0 pM (-pIC50?SEM: 10.4?0.04).
CAS:
1476847-58-1
Formula:
C24H18N4O4S2
Molecular Weight:
490.55
Purity:
0.98
SMILES:
COc1nn2cc(nc2s1)-c1cc2c(OCc3csc(n3)-c3ccccc3)cc(OC)cc2o1
References
1. MOL #106666; Contributions of PAR1 and PAR4 to thrombin induced GPIIbIIIa activation in human platelets; Matthew T. Duvernay, Kayla J. Temple,et al. Hamm Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232-6600; Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, TN 37232, USA KJT, ALB, SRS, CWL; Department of Chemistry, Vanderbilt University, Nashville, TN 37232, USA SRS, CWJ Molecular Pharmacology Fast Forward. Published on October 26, 2016 as DOI: 10.1124/mol.116.106666
2. Preparation of protease activated receptor 4 (PAR4) agonist peptides and their use as PAR4 receptor activation for measuring the activity of PAR4 antagonist imidazothiadiazole and imidazopyridazine derivatives and analogs; Kornacker, Michael G.; Mapelli, Claudio; Riexinger, Douglas James Assignee Bristol-Myers Squibb Company, USA; 2013; Patent Information; Oct 31, 2013; WO 2013163248 A1